BioSpace News Archive

NGM Bio today provided an update on the development of NGM282, a compound in Phase 2 clinical testing for the treatment of NASH.

Medidata, the leading global provider of cloud-based technology and data analytics for clinical research, today announced that it has been selected for the Fortune Future 50 list.

The company announced the pricing of a private placement of 3,360,000 shares of its common stock at a price of $6.00 per share.

TriNetX announced a move into their new, expanded headquarters in Cambridge to accommodate their rapidly growing business.

In advance of the call on November 9, 2017, Organovo will issue its fiscal second-quarter 2018 earnings press release.

Bamforth is a senior exec with thirty years of biologics experience including CDMO leadership.

Microbix Biosystems Inc. (TSX: MBX) (“Microbix” or the “Company”), a developer and marketer of biological products and technologies, announces that it has completed a brokered private placement financing totaling $2.33 million dollars, resulting in the issue of 7,784,500 million units (“Units”) at a price of $0.30 per unit.

This includes the full exercise of the underwriters’ option to purchase 750,000 additional shares, at the public offering price of $16.00 per share.

The company expects revenues for fiscal 2017, ended on September 30, 2017, to be approximately $200.5 million.

Pluristem’s ARS program is developed and funded by the U.S. National Institutes of Health and the U.S. Department of Defense, and is in preparation for a pivotal study.